FY2025 EPS Forecast for Ovid Therapeutics Lifted by Analyst

Key Points

• William Blair has revised its FY2025 earnings estimate for Ovid Therapeutics to ($0.50) per share, an improvement from the previous estimate of ($0.58).
• Ovid Therapeutics reported a quarterly earnings of ($0.06) EPS, surpassing analysts' expectations of ($0.16) EPS, and achieved a revenue of $6.27 million compared to a consensus estimate of just $0.09 million.
• The stock currently holds a consensus rating of "Buy" with a target price of $3.10, and 72.24% of the company’s shares are held by institutional investors.

Ovid Therapeutics (NASDAQ:OVID - Free Report) - Stock analysts at William Blair upped their FY2025 earnings per share (EPS) estimates for Ovid Therapeutics in a report issued on Wednesday, August 13th. William Blair analyst M. Minter now expects that the company will earn ($0.50) per share for the year, up from their previous forecast of ($0.58). William Blair currently has a "Strong-Buy" rating on the stock. The consensus estimate for Ovid Therapeutics' current full-year earnings is ($0.40) per share. William Blair also issued estimates for Ovid Therapeutics' Q1 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.72) EPS, FY2027 earnings at ($1.01) EPS, FY2028 earnings at ($1.13) EPS and FY2029 earnings at ($1.23) EPS.

Ovid Therapeutics (NASDAQ:OVID - Get Free Report) last issued its earnings results on Wednesday, August 13th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.10. Ovid Therapeutics had a negative return on equity of 58.87% and a negative net margin of 574.44%.The company had revenue of $6.27 million during the quarter, compared to the consensus estimate of $0.09 million.

Several other brokerages also recently weighed in on OVID. Wall Street Zen raised Ovid Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. HC Wainwright reduced their price target on Ovid Therapeutics from $2.00 to $1.50 and set a "buy" rating for the company in a report on Tuesday, May 27th. Finally, B. Riley reissued a "buy" rating and issued a $3.00 price target on shares of Ovid Therapeutics in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $3.10.

Ovid Therapeutics Stock Down 1.1%

Shares of NASDAQ OVID traded down $0.01 on Monday, hitting $0.94. The company had a trading volume of 574,096 shares, compared to its average volume of 968,782. Ovid Therapeutics has a 12-month low of $0.2425 and a 12-month high of $1.47. The business has a 50 day moving average of $0.49 and a two-hundred day moving average of $0.43. The company has a quick ratio of 4.72, a current ratio of 4.72 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $66.84 million, a P/E ratio of -1.76 and a beta of 0.20.

Institutional Trading of Ovid Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC raised its stake in Ovid Therapeutics by 12.8% during the first quarter. Acadian Asset Management LLC now owns 2,088,046 shares of the company's stock valued at $650,000 after buying an additional 237,445 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its position in Ovid Therapeutics by 15.0% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,150,000 shares of the company's stock valued at $359,000 after acquiring an additional 150,000 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Ovid Therapeutics by 50.2% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 943,416 shares of the company's stock valued at $881,000 after acquiring an additional 315,126 shares during the period. Affinity Asset Advisors LLC acquired a new stake in Ovid Therapeutics in the 1st quarter valued at approximately $208,000. Finally, Assenagon Asset Management S.A. increased its position in Ovid Therapeutics by 699.9% in the 1st quarter. Assenagon Asset Management S.A. now owns 560,830 shares of the company's stock valued at $175,000 after acquiring an additional 490,716 shares during the period. Institutional investors and hedge funds own 72.24% of the company's stock.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.